Trials / Conditions / Adenocarcinoma of the Esophagus

Adenocarcinoma of the Esophagus

18 registered clinical trials studyying Adenocarcinoma of the Esophagus — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Juncti NCT06161818	Erasmus Medical Center	Phase 2
Withdrawn	Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph NCT03307941	Jules Bordet Institute	Phase 1 / Phase 2
Withdrawn	C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced NCT02344810	Eastern Cooperative Oncology Group	Phase 1 / Phase 2
Unknown	FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients Wit NCT02037048	Case Comprehensive Cancer Center	Phase 2
Completed	Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esop NCT01612546	City of Hope Medical Center	Phase 2
Completed	Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer NCT01231399	City of Hope Medical Center	Phase 1 / Phase 2
Terminated	Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) NCT01395537	Case Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal NCT01212822	Fox Chase Cancer Center	Phase 2
Completed	Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have F NCT01129206	Ohio State University Comprehensive Cancer Center	Phase 2
Terminated	Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal NCT00573131	Boston Scientific Corporation	Phase 2
Completed	Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydroch NCT01561014	Wake Forest University Health Sciences	Phase 1
Completed	Nodal Status in Adenocarcinoma of the Esophagus an Cardia NCT01635595	University of Bologna	—
Terminated	FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer NCT00098527	National Cancer Institute (NCI)	Phase 2
Completed	3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastr NCT00077545	National Cancer Institute (NCI)	Phase 2
Terminated	A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer NCT00064259	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction NCT00061958	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer NCT00045526	National Cancer Institute (NCI)	Phase 2
Terminated	Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus NCT00003487	Burzynski Research Institute	Phase 2